Lee Wei-Chieh, Tsai Yi-Hsuan, Hsieh Yun-Yu, Fang Yen-Nan, Fang Chih-Yuan, Wu Po-Jui, Chen Huang-Chung, Liu Ping-Yen, Fang Hsiu-Yu
Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Int J Clin Pract. 2022 Dec 17;2022:2292379. doi: 10.1155/2022/2292379. eCollection 2022.
A target of low-density lipoprotein cholesterol (LDL-C) <70 mg/dL or ≥50% reduction should be set. This study aimed to explore the information required to attain the optimal goal of lipid control for patients with ACS in real-world practice using big database analysis.
Patients with ACS were enrolled between January 2005 and December 2019, and their medical history was obtained from the Chang Gung Research database. According to the attainment of LDL-C levels, the study population was divided into groups with and without ≥50% reduced LDL-C levels. In the group that achieved ≥50% reduced LDL-C levels, the study population was subdivided into groups with and without achievement of LDL-C level < 70 mg/dL.
This study enrolled 14,520 participants, out of whom only 3,367 patients (23.2%) achieved ≥50% reduced LDL-C levels. At the 3-year follow-up periods, higher incidences of cardiovascular (CV) mortality and all-cause mortality were absorbed in patients without ≥50% reduced LDL-C levels, especially in subgroups of hypertension and diabetes mellitus (DM). When comparing different percentages of reduced LDL-C levels, the significantly lowest hazard ratio (HR) of CV and all-cause mortality was noted at ≥50% reduced LDL-C levels (CV mortality; HR: 0.64; all-cause mortality; HR: 0.57).
In the ACS population, better clinical outcomes were yielded in patients with ≥50% reduced LDL-C levels, especially in the hypertension and DM populations. However, strict lipid control did not show better clinical outcomes in patients with ≥50% reduction and <70 mg/dL in LDL-C levels.
应设定低密度脂蛋白胆固醇(LDL-C)<70mg/dL或降低≥50%的目标。本研究旨在通过大数据分析,探索在现实世界实践中使急性冠状动脉综合征(ACS)患者达到脂质控制最佳目标所需的信息。
纳入2005年1月至2019年12月期间的ACS患者,其病史来自长庚研究数据库。根据LDL-C水平的达标情况,将研究人群分为LDL-C水平降低≥50%和未降低≥50%的组。在LDL-C水平降低≥50%的组中,将研究人群再细分为LDL-C水平<70mg/dL和未达到该水平的组。
本研究共纳入14520名参与者,其中只有3367名患者(23.2%)的LDL-C水平降低≥50%。在3年随访期内,LDL-C水平未降低≥50%的患者心血管(CV)死亡率和全因死亡率较高,尤其是高血压和糖尿病(DM)亚组。比较不同降低百分比的LDL-C水平时,LDL-C水平降低≥50%时CV和全因死亡率的危险比(HR)显著最低(CV死亡率;HR:0.64;全因死亡率;HR:0.57)。
在ACS人群中,LDL-C水平降低≥50%的患者临床结局更好,尤其是高血压和DM人群。然而,严格的脂质控制在LDL-C水平降低≥50%且<70mg/dL的患者中并未显示出更好的临床结局。